Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website

Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder

Click for list of published reports
Click for topic nomination form
Click for list of reports in progress

Subscribe to the
ESP Report RSS feed RSS feed icon
Evidence Brief:  Barriers and Facilitators to Use of Medications for Opioid Use Disorder

Prepared by:
Evidence Synthesis Program (ESP) Coordinating Center
Portland VA Health Care System
Portland, OR
Mark Helfand, MD, MPH, MS, Director

Recommended Citation:
Mackey K, Veazie S, Anderson J, Bourne D, and Peterson K. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2009.


Download PDF: Brief, Supplemental Materials

Purpose

The ESP Coordinating Center (ESP CC) is responding to a request from VA's Health Services Research and Development Service (HSR&D) for an evidence brief on barriers to and facilitators of use of buprenorphine and extended-release naltrexone for treatment of opioid use disorder (OUD). This review synthesizes evidence on the barriers and facilitators at the patient, provider, and health care system levels. Findings from this review will be used to inform prioritization of questions for a September 2019 State-of-the-Art (SOTA) conference.

Key Questions

Key Question 1: What are the patient, provider, and systems-level barriers and facilitators to use of buprenorphine and extended-release naltrexone for OUD?

Key Question 2: Do these barriers and facilitators vary by patient characteristics, provider characteristics, or setting?